Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.55), $0.03 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $43.6 million versus the consensus estimate of $44.32 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.